In brief
- A double-blind crossover trial from the University of Basel compared three doses of 2C-B with 125 mg of MDMA, 25 mg of psilocybin, and a placebo in 24 healthy volunteers.
- At 30 mg, 2C-B produced an overall effect comparable to MDMA, combining perceptual alterations with increased emotional empathy, lasting an average of five hours.
- The compound showed better cardiovascular tolerance than MDMA and fewer unpleasant effects than psilocybin, which did trigger acute anxiety.
2C-B has been circulating for four decades, yet rigorous controlled data on the compound has remained virtually nonexistent. A team at University Hospital Basel has now filled much of that gap with the first head-to-head study directly comparing it to MDMA and psilocybin, published in the July issue of Neuropsychopharmacology.
A Study Design Built for Meaningful Comparison
Twenty-four healthy participants—twelve women and twelve men—took part in a randomized, double-blind, placebo-controlled crossover trial where every participant went through each experimental condition. The researchers tested three doses of 2C-B—10, 20, and 30 mg—against 125 mg of MDMA and 25 mg of psilocybin. Having the same subject receive every substance substantially eliminates individual variability, yielding far more robust comparative data than what is typically seen in psychedelic research.
An Intermediate Profile
The 30 mg dose produced an “overall effect” comparable to that of MDMA and lower than psilocybin’s. Looking closer, 2C-B acted as a true hybrid: it induced psychedelic perceptual shifts alongside an increase in emotional empathy akin to MDMA. The mean duration of subjective effects was approximately 4.9 hours, virtually identical to MDMA’s and shorter than psilocybin’s 6.1 hours. Its pharmacokinetics scaled linearly with dose, showing a plasma half-life of roughly 1.3 hours.
The safety and qualitative differences proved just as illuminating. MDMA induced the highest cardiovascular stimulation and was the sole compound to elevate oxytocin levels. Psilocybin was the only drug to trigger anxiety and unpleasant effects. 2C-B fell right in the middle: less cardiovascular strain than MDMA and fewer distressing psychological effects than psilocybin. The authors conclude that it blends entactogenic and psychedelic qualities, occupying an intermediate space between the two.
What This Means
These findings carry practical value far beyond the lab. They corroborate through rigorous data what had long been described anecdotally—2C-B’s hybrid character and its steep dose-response curve—while establishing concrete benchmarks for duration and dosing that help anyone understand the substance’s pharmacological reality. For broader context, explore our guide to MDMA and empathogens.
Two important caveats warrant mention. First, this trial involved healthy volunteers, pharmaceutical-grade purity, precise dosing, and clinical supervision—none of which reflect typical conditions outside the laboratory, where weighing active doses in the single-milligram range is notoriously tricky and pre-consumption drug checking makes all the difference. Second, while 24 participants suffice for human pharmacology, the sample reveals nothing about repeat use or individuals with pre-existing conditions. Our harm reduction guide covers the essentials of drug checking and dose titration.
Source
- Arikci D, Borgulya J, Straumann I et al. Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with MDMA and psilocybin in a double-blind, placebo-controlled study in healthy participants. Neuropsychopharmacology 51(8):1511-1518, July 2026. DOI 10.1038/s41386-026-02428-9.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
